Press Releases


Copiague, NY, July 19, 2001– American Biogenetic Sciences, Inc. (ABS)(Nasdaq:MABA) announced three presentations at the XVIII Congress of The International Society on Thrombosis and Haemostasis in Paris, France, last week which provided additional valuable insights into the clinical utility of TpP, a patented test for measuring blood levels of Thrombus Precursor Protein (TpP™).

The studies suggest a broader range of potential uses for the company’s TpP test in excluding thrombosis in certain patient populations.

Dr. Michael Paidas and colleagues, Department of Ob/Gyn, New York University School of Medicine, New York, New York, presented data on TpP in the management of high risk pregnancies and noted a relationship between poor blood flow and birth weight and TpP levels.

Dr. Yale Arkel and colleagues, Maine Medical Center Research Institute, Portland, Maine, presented two papers evaluating the utility of TpP in various medical conditions including the monitoring of thrombosis in renal and oncology patients.

These abstracts can be viewed as follows: Markers Of The Increase In Thrombin Production In Multiple Gestation. M.J. Paidas, Y.S. Arkel, D.H. Ku, G. Urban, E. Kuczynski, H. Rogue, J. Maturi, S. Kahn, J. Schoenfeld, C.J. Lockwood. Dept. of Ob/Gyn NYU School of Medicine, NY, NY; Thrombosis research program, Maine Medical Center Research Institute, Portland, ME, USA Comparison Of ELISA For Soluble Fibrin Polymer (TpP) And D-Dimer In Patients With Renal Failure Or Malignancy (Not In Remission) And Not Having Clinical Evidence For Active Venous Thromboembolism. Y.S Arkel D.H. Ku, P. Le, A.M. Carr. Maine Medical Center Research Institute, S. Portland, ME USA Increased Thrombin Generation As Per Endogenous Thrombin Potential (ETP), Coagulation Activation Markers (TpP, TAT, And PF1.2) And TAFI Levels In Subjects Treated With Estrogen Hormone Replacement (HRT) Y.S Arkel, D. Spratt, D.H Ku, K. Becker T. Worster, P. Le, K.E Domey, H. Alves, S.C. Ku, V. Ku. Maine Medical Center Research Institute, S. Portland, Maine, USA

American Biogenetic Sciences, Inc., based in Copiague, N.Y., researches and develops diagnostic tests for cardio-pulmonary conditions and infectious diseases, as well as for new treatments for neurological disorders including epilepsy, migraine, mania, Parkinson’s disease and Alzheimer’s disease.

Statements in this press release that are not strictly historical are “forward looking” statements within the meaning of the Private Securities Litigation Reform Act of 1995, and should be considered as subject to various risks and uncertainties that could cause actual results to differ materially from those anticipated, including the risk that its products may not be commercialized. For further details and a discussion of these risks and uncertainties, see the Company's Securities and Exchange Commission filings including its annual report on Form 10K.


For a complete analysis of the ABS pipeline go to:


American Biogenetic Sciences, Inc. ©1999